iLIVER最新文献

{"title":"Liver transplantation and immune tolerance: Setting the stage for optimal post-transplant status","authors":"Jiaying Cao, Qi Ling","doi":"10.1016/j.iliver.2024.100097","DOIUrl":"10.1016/j.iliver.2024.100097","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100097"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000227/pdfft?md5=88237d48481d600184c150e90112c29a&pid=1-s2.0-S2772947824000227-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141138982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of efficacy and safety for the combination of regorafenib and PD-1 inhibitor in advanced hepatocellular carcinoma: A real-world clinical study","authors":"Zhongchao Li,&nbsp;Jingtao Zhong,&nbsp;Chengsheng Zhang,&nbsp;Bo Zhang,&nbsp;Xuetao Shi,&nbsp;Lei Li","doi":"10.1016/j.iliver.2024.100092","DOIUrl":"10.1016/j.iliver.2024.100092","url":null,"abstract":"<div><h3>Background and aims</h3><p>Hepatocellular carcinoma (HCC) is a prevalent and deadly disease with limited treatment options. Regorafenib, a tyrosine kinase inhibitor, has shown promise in HCC treatment but faces limitations as a monotherapy. Combining regorafenib with PD-1 inhibitor may improve efficacy and survival outcomes for patients. This retrospective analysis was conducted to explore its efficacy and safety, providing reference experience for better application of this combination therapy.</p></div><div><h3>Methods</h3><p>This retrospective single-center study evaluated the efficacy and safety of combining regorafenib with PD-1 blockade for patients with HCC. Efficacy was evaluated according to the RECIST 1.1 evaluation criteria. Safety was assessed using CTCAE 4.0. Data was analyzed to compare survival status in different subgroups.</p></div><div><h3>Results</h3><p>Generally, there were 76 patients with HCC elected to receive the regorafenib plus PD-1 blockade treatment during the study period. The objective response rate was 21.1% (<em>n</em> = 16), and the disease control rate was 56.6% (<em>n</em> = 43). Median progression-free survival (PFS) was 6.8 months, and median overall survival had not yet been reached. All patients suffered of at least 1 adverse event. Grade ≥3 adverse events occurred in 31.6% of patients (<em>n</em> = 24), with the most common being hand-foot syndrome, decreased appetite, and abdominal distension. Subgroup analyses showed no significant differences in PFS based on cirrhosis status or previous treatment lines.</p></div><div><h3>Conclusions</h3><p>With manageable safety, regorafenib combined PD-1 inhibitor could bring survival benefits for advanced HCC who have received systemic treatment. Further, the Cox analysis showed that HBV infection, metastasis, etc. did not have significant effects on the survival benefits.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100092"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000173/pdfft?md5=714108c0991fc3608cf1d3f3d027572c&pid=1-s2.0-S2772947824000173-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140405142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the future of liver disease research: A roadmap for iLIVER","authors":"Lei Cai,&nbsp;Ming-Da Wang,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2024.100084","DOIUrl":"https://doi.org/10.1016/j.iliver.2024.100084","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100084"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000094/pdfft?md5=118dead8c509dfd177b9b6c0e5ee1c03&pid=1-s2.0-S2772947824000094-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140096204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for esophagogastric variceal-related poor outcomes in primary biliary cholangitis: A prospective cohort study","authors":"Lin Han ,&nbsp;Huan Xie ,&nbsp;Xue-Mei Ma ,&nbsp;Xiao-Long Lu ,&nbsp;Jun Zhao ,&nbsp;Qing-Sheng Liang ,&nbsp;Zheng-Sheng Zou ,&nbsp;Jing-Feng Bi ,&nbsp;Bo Jin ,&nbsp;Ying Sun","doi":"10.1016/j.iliver.2024.100081","DOIUrl":"10.1016/j.iliver.2024.100081","url":null,"abstract":"<div><h3>Background and aims</h3><p>Esophagogastric varices (EGV) are common complications of primary biliary cholangitis (PBC). We examined the risk factors for variceal bleeding-related liver transplantation (LT) or death.</p></div><div><h3>Methods</h3><p>This prospective observational cohort study involved PBC in our hospital from 1 January 2005 to 1 January 2020. The clinical endpoints were variceal bleeding-related LT and death. Survival analysis was performed using the Kaplan–Meier estimate, cox regression analysis was performed to investigate risk factors.</p></div><div><h3>Results</h3><p>PBC with EGV had significantly shorter survival than those without (<em>p</em> = 0.002). Endoscopic prophylaxis significantly improved poor outcomes in PBC with EGV (<em>p</em> <em>&lt;</em> 0.001). Risk factors in patients with EGV included: cholinesterase (CHE) of &lt;1.0 × upper limit of normal (ULN), international normalized ratio (INR) of &gt;1.2 × ULN at baseline, total bilirubin of &gt;1.2 × ULN, aspartate aminotransferase (AST) of &gt;2.3 × ULN after 1 year of ursodeoxycholic acid (UDCA) treatment, non-biochemical responders according to the Paris criteria, and no history of endoscopic therapy. In PBC without EGV, risk factors included AST of &gt;2.3 × ULN, INR of &gt;1.2 × ULN at baseline, CHE of &lt;1.0 × ULN after 1 year of UDCA treatment, and GLOBE score of &gt;1.125.</p></div><div><h3>Conclusion</h3><p>This study provides evidence that AST, INR and CHE are major risk factors for variceal bleeding-related poor outcomes in PBC. For PBC with EGV, a good biochemical response to UDCA and endoscopic prophylaxis may improve survival. These findings can aid for guiding initial PBC risk stratification and screening endoscopy in patients without EGV.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100081"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000069/pdfft?md5=b86f241c6c5e865ce844c195f7d4042e&pid=1-s2.0-S2772947824000069-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139813751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publication characteristics and visualized analysis of research about liver sinusoidal endothelial cells","authors":"Shanshan Zhao ,&nbsp;Lan Zhang ,&nbsp;Junzhe Zhao ,&nbsp;Farah Tasnim ,&nbsp;Hanry Yu","doi":"10.1016/j.iliver.2023.11.002","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.11.002","url":null,"abstract":"<div><h3>Background and aims</h3><p>Through visual analysis of related literature, the main research direction and hot spots of liver sinusoidal endothelial cells (LSECs) in recent 24 years were explored.</p></div><div><h3>Methods</h3><p>This study used bibliometric analysis with CiteSpace, VOSviewer, Biblioshiny and online analytic tool <span>bibliometric.com</span><svg><path></path></svg> to provide a quantitative analysis, hot spot mining, and commentary of articles published in the field of LSECs research. The relevant literature in the Web of Science Core Collection (WOSCC) was searched from 2000 to 2023. The publications with topics or titles or keywords containing LSECs were included into this study. The countries, organizations, journals, authors, and keywords of the publications were summarized and analyzed.</p></div><div><h3>Results</h3><p>This study included 3,747 publications from 14,132 authors belonging to 389 institutions in 61 countries/regions and published in 150 journals, with 156,309 citations. The United States contributed most (1,150) to the publications. The most productive institution was the University of Sydney. <em>Hepatology</em> accounts for the most output (293, 7.8​%), European authors had a widespread cooperation. The most productive author was Adam DH with 68 papers. Immunological function of LSECs is research hot spot.</p></div><div><h3>Conclusion</h3><p>This study highlights key trends based on a large dataset of the most influential publications about LSECs research over a 24-year period. It provides important clues and ideas for researchers focusing in this area and facilitates future liver disease mechanism, understanding, and treatment.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100075"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947823000506/pdfft?md5=ecdacfaa6950185d24d1155ccad17e0a&pid=1-s2.0-S2772947823000506-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomic features on contrast-enhanced images of the remnant liver predict the prognosis of hepatocellular carcinoma after partial hepatectomy","authors":"Meilong Wu ,&nbsp;Liping Liu ,&nbsp;Xiaojuan Wang ,&nbsp;Ying Xiao ,&nbsp;Shizhong Yang ,&nbsp;Jiahong Dong","doi":"10.1016/j.iliver.2024.100079","DOIUrl":"10.1016/j.iliver.2024.100079","url":null,"abstract":"<div><h3>Background and aims</h3><p>Radiomic features extracted from preoperative contrast-enhanced computed tomography (CT) images have been shown to predict the prognosis of hepatocellular carcinoma (HCC). However, the prognostic role of radiomic features obtained from postoperative contrast-enhanced CT images of the remnant liver remains unclear. This study explored the prognostic value of radiomic features extracted from postoperative contrast-enhanced CT images in patients with HCC.</p></div><div><h3>Methods</h3><p>Robust radiomic features were obtained from postoperative contrast-enhanced CT images for 78 patients with primary HCC and used to construct a radiomics score. A clinical model and a combined model that integrated clinicopathological indicators and the radiomics score were established. The predictive performance of the model was assessed using the concordance index and net reclassification index.</p></div><div><h3>Results</h3><p>The postoperative radiomics score for the remnant liver was an independent prognostic factor for disease-free survival (DFS) and overall survival (OS). The combined model was not inferior to the clinical model in predicting DFS but was superior in predicting OS. The net reclassification index confirmed that the combined model was more accurate and efficient in predicting OS and DFS. The radiomics score for DFS was significantly associated with tumor thrombus in the portal vein and the postoperative neutrophil-lymphocyte ratio. The radiomics score for OS was associated with multiple tumors, microvascular invasion, and tumor thrombus in the portal vein.</p></div><div><h3>Conclusion</h3><p>Postoperative contrast-enhanced CT radiomic features of the remnant liver were valuable prognostic indicators that could potentially reflect tumor burden and postoperative inflammatory status and provide more information for clinical decision-making.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100079"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000045/pdfft?md5=c065aba55254c61a1225a54fc0d41961&pid=1-s2.0-S2772947824000045-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139820567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volatile organic compounds for the detection of hepatocellular carcinoma—A scoping review","authors":"Sayed Metwaly ,&nbsp;Alicja Psica ,&nbsp;Opeyemi Sogaolu ,&nbsp;Irfan Ahmed ,&nbsp;Ashis Mukhopadhya ,&nbsp;Mirela Delibegović ,&nbsp;Mohamed Bekheit","doi":"10.1016/j.iliver.2023.09.001","DOIUrl":"10.1016/j.iliver.2023.09.001","url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is an increasingly common and the second leading cause of cancer mortality worldwide with a 5-year survival rate about 12%. Less than 20% of HCC patients are eligible to curative treatment owing to the late presentation. Clearly, there is a need for a readily accessible, early screening tool. This scoping review critically appraises and synthesizes the current published knowledge about the use of exhaled volatile organic compounds (VOCs) as a potential noninvasive means for HCC detection aiming to advance this nascent field. A systematic electronic search was conducted. The search strategy included all studies published until the 24th of March 2023 using a combination of relevant keywords. The search yielded 9 publications using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Two of the studies described in vitro experiments, and seven clinical studies were conducted on small groups of patients. Overall, 42 headspace gases were analyzed in the in vitro studies. Combined, the clinical studies included 420 HCC patients and 630 controls. The studies reported potential role for a combination of VOCs in the diagnosis of HCC. However, there is lack of consensus. Although there appears to be promise in VOCs research associated with HCC, there is no single volatile biomarker in exhaled breath attributed to HCC and data from extracted studies indicates a lack of standardization. Large multicentre population studies are required to verify the existence of VOCs linked to HCC.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100070"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947823000452/pdfft?md5=cd14d50b37f5452cfcfbeb72231a1ecc&pid=1-s2.0-S2772947823000452-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135607246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma","authors":"Ming-Da Wang ,&nbsp;Yong-Kang Diao ,&nbsp;Lan-Qing Yao ,&nbsp;Zhong-Qi Fan ,&nbsp;Ke-Chun Wang ,&nbsp;Han Wu ,&nbsp;Li-Hui Gu ,&nbsp;Jia-Hao Xu ,&nbsp;Chao Li ,&nbsp;Guo-Yue Lv ,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2024.100083","DOIUrl":"10.1016/j.iliver.2024.100083","url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is a prevalent malignancy worldwide, ranking as the sixth most common malignancy and the third leading cause of cancer-related mortality. Late diagnosis, limited management options, and its complex etiology contribute to the poor prognosis and high mortality rates. Recent advances in understanding the molecular mechanisms of HCC and innovations in high-throughput sequencing technologies have led to the development of molecular diagnostics and personalized therapies for this challenging malignancy. This review provides a comprehensive overview of research on the molecular diagnosis and individualized treatment for HCC. We highlight key advances and potential future directions and discuss the application of next-generation sequencing technologies to identify and characterize genetic and epigenetic alterations in HCC patients. These technologies may aid in the selection of targeted therapies, prediction of treatment response, and monitoring disease progression. Furthermore, we explore the role of liquid biopsy in HCC diagnosis, prognosis prediction, and treatment monitoring, focusing on circulating tumor cells, circulating tumor DNA, and extracellular vesicles. We also explore the evolving landscape of personalized therapy for HCC, including targeted therapies against key oncogenic signaling pathways, immune checkpoint inhibitors, tumor-agnostic therapies, and innovative cell-based therapies. We discuss the challenges and opportunities that lie ahead in the quest to improve HCC patient outcomes through the integration of molecular diagnostics and individualized precision therapies. We emphasize the need for multi-interdisciplinary collaboration, refinement of predictive and prognostic biomarkers, and the development of more effective combination strategies for HCC management in the new area of precision medicine.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100083"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000082/pdfft?md5=bd51dc230c2eaf9accdb3562d7e30e85&pid=1-s2.0-S2772947824000082-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139873264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence-based pathological analysis of liver cancer: Current advancements and interpretative strategies","authors":"Guang-Yu Ding ,&nbsp;Jie-Yi Shi ,&nbsp;Xiao-Dong Wang ,&nbsp;Bo Yan ,&nbsp;Xi-Yang Liu ,&nbsp;Qiang Gao","doi":"10.1016/j.iliver.2024.100082","DOIUrl":"10.1016/j.iliver.2024.100082","url":null,"abstract":"<div><p>In recent years, significant advances have been achieved in liver cancer management with the development of artificial intelligence (AI). AI-based pathological analysis can extract crucial information from whole slide images to assist clinicians in all aspects from diagnosis to prognosis and molecular profiling. However, AI techniques have a “black box” nature, which means that interpretability is of utmost importance because it is key to ensuring the reliability of the methods and building trust among clinicians for actual clinical implementation. In this paper, we provide an overview of current technical advancements in the AI-based pathological analysis of liver cancer, and delve into the strategies used in recent studies to unravel the “black box” of AI's decision-making process.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100082"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000070/pdfft?md5=066fabb4fd4ae8d1a5a1663b2066d90e&pid=1-s2.0-S2772947824000070-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139875057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential role of extracellular vesicles as hepatic diagnostic and therapeutic tools: Can the dream come true?","authors":"Nourhan Badwei","doi":"10.1016/j.iliver.2024.100078","DOIUrl":"10.1016/j.iliver.2024.100078","url":null,"abstract":"<div><p>Chronic liver disease of various aetiologies with underlying cirrhosis is a serious cause of liver-related morbidity and mortality globally. The emerging role of non-invasive diagnostic/therapeutic tools in different stages of liver disease represents a challenge and an area of great interest for many researchers, which could differ in the clinical outcome of liver disease patients. Over a decade, several studies have evaluated the emerging role of circulating extracellular vesicles (EVs) as biomarkers and therapeutic targets in different liver diseases; They are small membrane-encapsulated particles that can act as potent vehicles via their cargos between different hepatic cell types and also between organs, because of their ability to transfer proteins, lipids, and nucleic acids to affect the recipient cells' related physiological functions. Hence, the issues related to the potential use of EVs as biomarkers in liver disease diagnosis, prognosis, and even to assess the response to treatment, have been handled in our review concluding that EVs have shown promising results as potential diagnostic tools and for further evaluation as therapeutic targets.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100078"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000033/pdfft?md5=e2a429e7cf7c88e97b724fa454068312&pid=1-s2.0-S2772947824000033-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139831606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}